Share
mRNA Therapeutics Market: By Type (Self-Amplifying mRNA Vaccines and Conventional Non-Amplifying mRNA Vaccines), By Application (Cancer Immunotherapy, Allergy Tolerization, Therapeutic Vaccines, Protein Replacement), And Region - Global Analysis of Market Size, Share & Trends For 2019-2020 And Forecasts To 2031
Vaccines are simply biological preparations that provide active acquired immunity to a specific disease. The mRNA vaccine is a nucleic acid-based vaccine that contains messenger RNAs, which enable the patient's cells to produce proteins as part of a treatment option. These vaccines have self-adjuvant properties. To generate a strong immune response, the mRNA vaccine uses the host cell machinery to translate the mRNA into its corresponding antigen. The use of mRNA vaccines eliminates the possibility of infectious particles being produced in the body.
Global mRNA Therapeutics to surpass USD 154.12 billion by 2031 from USD 47.96 billion in 2021 at a CAGR of 16.4% in the coming years, i.e., 2021-31. The market for mRNA vaccine is gaining traction as a result of its growing popularity, as it offers numerous advantages over other nucleic acid-based vaccines. The mRNA Vaccine can be produced quickly and cheaply, which increases their market demand.
Global mRNA Therapeutics market is classified on the basis of Type into Self-Amplifying mRNA Vaccines and Conventional Non-Amplifying mRNA Vaccines. Self-amplifying mRNAs derived from positive-strand RNA virus genomes have recently emerged as a promising technology platform for vaccine development. Non-virally delivered self-amplifying mRNA vaccines have the potential to be highly versatile, potent, streamlined, scalable, and affordable, thus driving market growth.
Based on application, global MRNA Therapeutics Market is fragmented into Cancer Immunotherapy, Allergy Tolerization, Therapeutic Vaccines, Protein Replacement and Others. The use of Therapeutic Vaccines is attributed to the growth in this segment. These are a new type of vaccine that is primarily used to treat viral infections and various types of cancer. A therapeutic vaccine aids the immune system in recognising a foreign agent such as cancerous cells or viruses.
The market for mRNA vaccine is gaining traction as a result of its growing popularity, as it offers numerous advantages over other nucleic acid-based vaccines. Because mRNA vaccines can be produced quickly and cheaply, they are in high demand in the market. The market has been fueled by increased research activities on the development of mRNA vaccines for various chronic diseases, including novel Coronaviruses. Furthermore, such vaccines have fewer negative effects on the body, allowing them to effectively improve disease conditions. The Global mRNA Vaccine Market is also being driven by an increase in the prevalence of cancer, genetic disorders, and viral infections, as well as an increase in vaccination awareness.
The Global mRNA Vaccine Market is expected to grow in tandem with advancements in the service industry. Furthermore, the unprecedented value of catering to the requirements and needs of a wide range of sectors has brought mRNA Vaccine products to the forefront of the spotlight. During the forecast period, the global market is expected to be driven by the COVID-19 outbreak and an increase in the number of prominent market players conducting clinical trials for vaccine development.
The high capital investment requirements and data management concerns are expected to limit the growth of this market to some extent. High research investment, high failure rates, and medication delivery challenges are all issues limiting market growth for firms in this industry.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Global MRNA Therapeutics market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Research activities for RNA-based therapeutics are increasing in North America as a result of significant infrastructure for developmental research, the availability of substantial research funds, and growing government initiatives toward RNA-based therapeutics, which are expected to drive the RNA-based therapeutics market growth.
The COVID-19 pandemic is an unprecedented global public health challenge that is expected to have a negative impact on the RNA-based therapeutics market. mRNA vaccines could potentially provide long-term solutions all over the world for diseases ranging from influenza to AIDS, but the RNA-based therapeutics market has decreased due to lockdown and temporary closure of research institutes and academic research.
REPORT ATTRIBUTE |
DETAILS |
|
Market size value in 2021 |
USD 154.96 billion |
|
Revenue forecast in 2031 |
USD 47.12 billion |
|
Growth Rate |
CAGR of 16.4% from 2021 to 2031 |
|
Base year for estimation |
2020 |
|
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Type, Application and Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
|
Key companies profiled |
Tiba Biotech, Moderna, Inc., Regulus Therapeutics, BioNTech AG, Dicerna Pharmaceuticals, eTheRNA Immunotherapies, ethris GmbH, In-Cell-Art, Sangamo Therapeutics, Inc. and Other Prominent Players. |
mRNA Therapeutics market size was estimated at USD 47.96 billion in 2021 and is expected to reach USD 154.12 billion in 2031.
The mRNA vaccine is a nucleic acid-based vaccine that contains messenger RNAs, which enable the patient's cells to produce proteins as part of a treatment option.
Therapeutic Vaccines and Self-Amplifying mRNA Vaccines accounted for the largest MRNA Therapeutics market share.
Key players: Tiba Biotech, Moderna, Inc., Regulus Therapeutics, BioNTech AG, Dicerna Pharmaceuticals are the key players in the MRNA Therapeutics market.
The market for mRNA vaccine is gaining traction as a result of its growing popularity, as it offers numerous advantages over other nucleic acid-based vaccines.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
